Applied dna announces linear dna orders from new contract research customers for use in rna vaccine and adeno-associated virus applications

Stony brook, n.y.--(business wire)---- $apdn #aav--applied dna sciences, inc. (nasdaq: apdn) (“applied dna” or the "company"), a leader in polymerase chain reaction (pcr)-based dna manufacturing, announced that it received orders for its linear dna to be evaluated in an rna vaccine and adeno-associated virus (aav) production from two new contract research customers, respectively. the company also received a follow-on order for linear dna from an existing contract research customer for a preclinical car t ther
APDN Ratings Summary
APDN Quant Ranking